Gold Investment Management Ltd. Grows Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Gold Investment Management Ltd. increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 12.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 82,147 shares of the company’s stock after buying an additional 8,943 shares during the quarter. Gold Investment Management Ltd.’s holdings in Takeda Pharmaceutical were worth $1,088,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of TAK. Pathstone Holdings LLC grew its position in shares of Takeda Pharmaceutical by 1.0% in the third quarter. Pathstone Holdings LLC now owns 430,676 shares of the company’s stock valued at $6,124,000 after purchasing an additional 4,280 shares during the period. Caprock Group LLC raised its holdings in shares of Takeda Pharmaceutical by 7.7% during the 3rd quarter. Caprock Group LLC now owns 34,304 shares of the company’s stock worth $488,000 after acquiring an additional 2,454 shares during the period. West Family Investments Inc. acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at about $254,000. Advisors Asset Management Inc. lifted its holdings in Takeda Pharmaceutical by 41.4% in the third quarter. Advisors Asset Management Inc. now owns 51,226 shares of the company’s stock valued at $728,000 after acquiring an additional 14,992 shares during the last quarter. Finally, Smithfield Trust Co lifted its stake in shares of Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after purchasing an additional 1,490 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $15.02 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The stock has a market cap of $47.78 billion, a PE ratio of 37.54, a P/E/G ratio of 0.24 and a beta of 0.46. The firm has a 50-day simple moving average of $13.76 and a two-hundred day simple moving average of $13.90. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.22.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.